Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of Farxiga (dapagliflozin) versus other glucose-lowering medicines in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i).

Next Previous
Trial Profile

A Study of Farxiga (dapagliflozin) versus other glucose-lowering medicines in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i).

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary) ; Canagliflozin; Empagliflozin; Ipragliflozin; Luseogliflozin; Tofogliflozin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CVD-REAL 2

    • Most Recent Events

    • 01 Jun 2021 Results comparing the risk of HHF or death in T2D patients starting SGLT2inhibitors versus other glucose lowering drugs (OGLDs) according to baseline LVEF published in the Diabetes, Obesity and Metabolism
    • 19 Jun 2018 According to an AstraZeneca media release, data from this trial will be presented at the American Diabetes Association's (ADA) 78th Scientific Sessions 2018.
    • 19 Mar 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top